MovDisordV3, Main, Exploration, bibRecord, 000873

Obstacles to the development of a neuroprotective therapy for Parkinson's disease.

Identifieur interne : 000873 ( Main/Exploration ); précédent : 000872; suivant : 000874

Obstacles to the development of a neuroprotective therapy for Parkinson's disease.

Auteurs : Fabrizio Stocchi [Italie] ; C Warren Olanow

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.

RBID : pubmed:23390094

English descriptors

KwdEn :
- Animals, Clinical Trials as Topic (economics), Disease Models, Animal, Disease Progression, Drug Discovery (economics), Drug Discovery (methods), Drug Discovery (trends), Humans, Neuroprotective Agents (therapeutic use), Parkinson Disease (etiology), Parkinson Disease (therapy).
MESH :
- chemical , therapeutic use : Neuroprotective Agents.
- economics : Clinical Trials as Topic, Drug Discovery.
- etiology : Parkinson Disease.
- methods : Drug Discovery.
- therapy : Parkinson Disease.
- trends : Drug Discovery.
- Animals, Disease Models, Animal, Disease Progression, Humans.

Abstract

A neuroprotective or disease-modifying therapy that can slow or stop disease progression and prevent the development of intolerable disability is the major unmet medical need in the treatment of Parkinson's disease (PD). Many putative neuroprotective agents have been identified in the laboratory, but none has been unequivocally demonstrated to provide disease-modifying effects in PD patients, even when clinical trials are positive. Obstacles to defining a neuroprotective therapy in PD include: (1) uncertainty about the cause of PD and precisely what to target, (2) a reliable animal model in which to test putative neuroprotective agents that accurately predicts results in PD patients, (3) insight about which dose to employ in clinical trials and which patient group to study, (4) a clinical trial design that reliably differentiates disease-modifying and symptomatic effects and that is acceptable to regulatory authorities, and (5) the cost and time of the development program. Advances have been made in each of these areas, thereby increasing the prospects of developing a neuroprotective or disease-modifying therapy in the not-too-distant future. These issues are reviewed in the present article.

DOI: 10.1002/mds.25337
PubMed: 23390094

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Obstacles to the development of a neuroprotective therapy for Parkinson's disease.</title>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation wicri:level="3"><nlm:affiliation>IRCCS San Raffaele Pisana, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS San Raffaele Pisana, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="doi">10.1002/mds.25337</idno>
<idno type="RBID">pubmed:23390094</idno>
<idno type="pmid">23390094</idno>
<idno type="wicri:Area/PubMed/Corpus">000A75</idno>
<idno type="wicri:Area/PubMed/Curation">000A75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000887</idno>
<idno type="wicri:Area/Ncbi/Merge">003A06</idno>
<idno type="wicri:Area/Ncbi/Curation">003A06</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003A06</idno>
<idno type="wicri:Area/Main/Merge">000873</idno>
<idno type="wicri:Area/Main/Curation">000873</idno>
<idno type="wicri:Area/Main/Exploration">000873</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Obstacles to the development of a neuroprotective therapy for Parkinson's disease.</title>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation wicri:level="3"><nlm:affiliation>IRCCS San Raffaele Pisana, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS San Raffaele Pisana, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Clinical Trials as Topic (economics)</term>
<term>Disease Models, Animal</term>
<term>Disease Progression</term>
<term>Drug Discovery (economics)</term>
<term>Drug Discovery (methods)</term>
<term>Drug Discovery (trends)</term>
<term>Humans</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (etiology)</term>
<term>Parkinson Disease (therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Drug Discovery</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Discovery</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Disease Progression</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A neuroprotective or disease-modifying therapy that can slow or stop disease progression and prevent the development of intolerable disability is the major unmet medical need in the treatment of Parkinson's disease (PD). Many putative neuroprotective agents have been identified in the laboratory, but none has been unequivocally demonstrated to provide disease-modifying effects in PD patients, even when clinical trials are positive. Obstacles to defining a neuroprotective therapy in PD include: (1) uncertainty about the cause of PD and precisely what to target, (2) a reliable animal model in which to test putative neuroprotective agents that accurately predicts results in PD patients, (3) insight about which dose to employ in clinical trials and which patient group to study, (4) a clinical trial design that reliably differentiates disease-modifying and symptomatic effects and that is acceptable to regulatory authorities, and (5) the cost and time of the development program. Advances have been made in each of these areas, thereby increasing the prospects of developing a neuroprotective or disease-modifying therapy in the not-too-distant future. These issues are reviewed in the present article.</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
<region><li>Latium</li>
</region>
<settlement><li>Rome</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
</noCountry>
<country name="Italie"><region name="Latium"><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000873 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000873 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23390094
   |texte=   Obstacles to the development of a neuroprotective therapy for Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23390094" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Obstacles to the development of a neuroprotective therapy for Parkinson's disease.

Obstacles to the development of a neuroprotective therapy for Parkinson's disease.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.